Boost For Oral SERDs As Menarini/Radius’ Orserdu Becomes First Approved For Breast Cancer

Following US FDA Approval

The firms’ Orserdu has won a US thumbs up for the treatment of ESR1-mutated advanced or metastatic breast cancer, marking a positive breakthrough for the challenging SERD drug class.  

Pair of hands on the red ground of a race track, with a white number one painted on it
Menarini And Radius Have Won The Race For The First Oral SERD • Source: Shutterstock

Menarini Group/Radius Health, Inc.’s oral selective estrogen receptor degrader (SERD) Orserdu has received approval from the US Food and Drug Administration in breast cancer but only for a subset of patients, nevertheless, it is a milestone that analysts say could positively affect the rest of the pipeline.

The drug, which contains the active ingredient elacestrant, was given the green light for postmenopausal women and adult men with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

Pipeline Watch: Ten Approvals And Seventeen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Defying Gravity: Five Drugs That Surpassed Their Sales Forecasts

 

Many assets outperform their pre-launch sales predictions despite the frequent overestimation of forecasts within the industry. In this article, Scrip highlights several such assets and the factors that influenced their predictions.

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

 

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.

Pipeline Watch: Eight Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Saudi Arabia Plans Advanced Manufacturing Campus Under Biotech Drive

 
• By 

A partnership with Germfree Laboratories will bring a new facility to boost Saudi Arabia’s biotech sector as the world’s largest oil exporter tries to establish itself as a global biotech hub by 2040.

Bitcoin Player Parataxis To Acquire Bridge Biotherapeutics After IPF Failure

 
• By 

After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.

Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

 
• By 

Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.